Azalea Therapeutics Scores an 82M Raise
Therapeutics has bloomed with $82 million in funding and a dual-vector approach that the company hopes can enable permanent genome editing with a single dose
Therapeutics has bloomed with $82 million in funding and a dual-vector approach that the company hopes can enable permanent genome editing with a single dose